# Amyloid Solution

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amyloid-solution

- Industry: Biotechnology
- Headquarters: Seongnam, South Korea
- Website: www.amyloidsolution.com
- Total disclosed funding: $59M
- Latest round: Series C (May 3, 2022)
- Investors on record: 18

## About

Based in Gyeonggi-do, South Korea, and founded in 2017 by CEO Jintae Chang, CSO YoungSoo Kim, and Jaeheuk Choi, Amyloid Solution Inc., a.k.a. Amyloid Solution is a health technology company that focuses on discovering and providing effective, safe, and diverse therapeutic solutions to overcome Alzheimer's disease. The company collaborates with international and domestic biopharma industries and scientists to search for fundamental culprits, interpret systemic interactions, and discover methods for varied patient cases. As of December 2022, the company operates three programs, which are amyloid, immunity, and homeostasis. In May 2022, Amyloid Solution Inc. raised KRW 38.3 billion in a Series C funding from SK Securities, Korea Investment & Securities, Industrial Bank of Korea, Heungkuk Securities, Xinova Investment, Meta Investment, KDB Industrial Bank, POSCO Capital, and T.S. Investment.

The company’s product line includes AS-S701, a small molecule drug that directly disaggregates all types of amyloid-ß aggregates, including oligomers and plaques, into non-toxic monomers; and AS-M801, a toll-like receptor-2 (TLR2) antagonistic monoclonal antibody to suppress the inflammatory response. Amyloid Solution also developing several other products, including S603, M302, N402, N403, and S204.

Amyloid Solution Inc. plans to use its proceeds from May 2022 funding to propagate its preclinical research with the goal of applying a Phase 1 clinical trial in 2023. In addition, the company will be collaborating with other drug tech companies to speed up the discovery of new targets and drug design.

## Funding rounds

- Series C, May 3, 2022, $30M — Korea Development Bank, Korea Investment & Securities, Posco Investment, T.S. Investment, Heungkuk Securities, IBK Capital, Meta Investment, SK Securities, Xinova Investment
- Series B, Jun 20, 2020, $1.6M — KB Investment, Posco Investment
- Series B, Apr 7, 2020, $15M — Korea Development Bank, Posco Investment, T.S. Investment, Medytox Venture Investment, Yuhan Corporation, KClavis Investment
- Series A, Mar 26, 2019, $13M — Innopolis Partners, WOORI Venture Partners, WONIK Investment Partners, T.S. Investment, Saehan Venture Capital, Stassets Investment

## Investors

- Innopolis Partners (https://capitalatlas.ai/funds/innopolis-partners) — Series A
- WOORI Venture Partners (https://capitalatlas.ai/funds/woori-venture-partners) — Series A
- WONIK Investment Partners (https://capitalatlas.ai/funds/wonik-investment-partners) — Series A
- T.S. Investment (https://capitalatlas.ai/funds/t-s-investment) — Series A, Series B, Series C
- Saehan Venture Capital (https://capitalatlas.ai/funds/saehan-venture-capital) — Series A
- Stassets Investment (https://capitalatlas.ai/funds/stassets-investment) — Series A
- Korea Development Bank (https://capitalatlas.ai/funds/korea-development-bank) — Series B, Series C
- Posco Investment (https://capitalatlas.ai/funds/posco-investment) — Series B, Series C
- Medytox Venture Investment (https://capitalatlas.ai/funds/medytox-venture-investment) — Series B
- Yuhan Corporation — Series B
- KClavis Investment (https://capitalatlas.ai/funds/kclavis-investment) — Series B
- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series B
- Korea Investment & Securities (https://capitalatlas.ai/funds/korea-investment-securities) — Series C
- Heungkuk Securities — Series C
- IBK Capital (https://capitalatlas.ai/funds/ibk-capital) — Series C
- Meta Investment (https://capitalatlas.ai/funds/meta-investment) — Series C
- SK Securities — Series C
- Xinova Investment (https://capitalatlas.ai/funds/xinova-investment) — Series C